At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)
In Brief
A Phase 2 clinical trial evaluating IFN beta 1a 44 mcg TIW, Curcumin, and 1 other intervention for Multiple Sclerosis. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This is a prospective, monocentric, double blind, placebo controlled, two arm study. Curcumin is derived from the rhizomes of the plant Curcuma longa (common name, turmeric) belonging to the Zingiberaceae family found in South Asian countries, especially India which is the largest producer. BCM95 (bioCurcumin) is a combination of a Curcumin extract and oil to enhance the bio-absorbability in humans. BCM95 may enhance and prolong the antioxidant and anti-inflammatory effects of the standard therapy maintaining a good safety profile.
Study Details
Timeline
Interventions
Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
Subjects received placebo matched to curcumin orally twice a day for 24 months.